Share price · IKT
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when IKT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 10 Nov 2026-7.7%
- 9 Nov 2026+12.0%
Nothing announced by IKT that day or the session before.
- 3 Nov 2026-3.9%
Nothing announced by IKT that day or the session before.
- 30 Oct 2026-7.2%
Nothing announced by IKT that day or the session before.
- 26 Oct 2026-4.4%
Nothing announced by IKT that day or the session before.
- 16 Oct 2026-9.8%
Nothing announced by IKT that day or the session before.
- 4 Aug 2026+10.4%
Nothing announced by IKT that day or the session before.
- 23 Jul 2026+7.4%
- 20 Jul 2026+5.7%
Nothing announced by IKT that day or the session before.
- 18 Jun 2026+8.9%
Nothing announced by IKT that day or the session before.
Share of unusual movement by asset
For each asset, the share of IKT's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 25% |
| Sessions with no dated event | — | 75% |
No dated announcements about its assets since 2 Jul 2024.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | PDGFR (imatinib-class)Small molecule | Pulmonary Arterial Hypertension | |
| Phase 2 | c-AblSmall molecule | Parkinson's Disease |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $15M | $52M+ $142M short-term inv. | $20M-$17M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0 | $13M | $31M+ $128M short-term inv. | $20M-$12M operating cash flow | report ↗ |
| 2026-Q1 | $0 | $11M | $50M+ $121M short-term inv. | $16M-$12M operating cash flow | report ↗ |
| 2025-Q3 | $0 | $7.7M | $38M+ $39M short-term inv. | $12M-$11M operating cash flow | report ↗ |
| 2025-Q2 | $0 | $5.3M | $78M+ $9.9M short-term inv. | $9.9M-$5.6M operating cash flow | report ↗ |
| 2025-Q1 | $0 | $11M | $73M+ $20M short-term inv. | $14M-$4.1M operating cash flow | report ↗ |
| 2024-Q3 | $0 | $4.2M | $0.9M+ $2.3M short-term inv. | $5.8M-$4.9M operating cash flow | report ↗ |
| 2024-Q2 | $0 | $3.1M | $3.1M+ $4.8M short-term inv. | $5.0M-$5.0M operating cash flow | report ↗ |
| 2024-Q1 | $0 | $2.8M | $2.4M+ $7.4M short-term inv. | $4.7M-$3.9M operating cash flow | report ↗ |
| 2023-Q3 | $0.1M | $3.2M | $15M+ $2.0M short-term inv. | $4.6M-$4.1M operating cash flow | report ↗ |
| 2023-Q2 | $0.1M | $4.5M | $1.9M+ $19M short-term inv. | $5.8M-$4.6M operating cash flow | report ↗ |
| 2023-Q1 | $0.1M | $2.9M | $4.0M+ $22M short-term inv. | $4.5M-$6.0M operating cash flow | report ↗ |
| 2022-Q3 | <$0.1M | $3.0M | $5.8M+ $21M short-term inv. | $4.5M-$5.5M operating cash flow | report ↗ |
| 2022-Q2 | <$0.1M | $3.0M | $32M | $4.6M-$4.4M operating cash flow | report ↗ |
| 2022-Q1 | $0.1M | $3.0M | $37M | $4.6M-$3.9M operating cash flow | report ↗ |
| 2021-Q3 | $0.3M | $3.1M | $45M | $4.5M-$2.0M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $30M | $139M+ $40M short-term inv. | $12M-$28M operating cash flow | report ↗ |
Inhibikase Therapeutics reported no disclosed revenue for 2025 (prior year $0M), with R&D spend of $29.79M, up 73.1% YoY. Cash and equivalents were $139.22M, while total cash, cash equivalents and marketable securities were $178.8M as of December 31, 2025. The company reported a net loss of $48.26M, or $0.49 per share, for the year.
The company is advancing IKT-001 into the global pivotal Phase 3 IMPROVE-PAH study in pulmonary arterial hypertension, with regulatory submissions filed in over 20 countries, first U.S. sites activated, and acceptance under the EU FAST-EU pilot initiative. The two-part adaptive study includes Part A in approximately 140 patients with a primary endpoint of pulmonary vascular resistance at Week 24, and Part B in approximately 346 patients with a primary endpoint of six-minute walk distance at Week 24, expected to run at up to about 180 sites worldwide. Inhibikase also completed a $115 million underwritten public offering in November 2025 and completed pre-clinical studies supporting a potential FDA Orphan Drug Designation application for IKT-001.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $0 | $17M | $56M+ $41M short-term inv. | $6.9M-$19M operating cash flow | report ↗ |
| 2023-FY | $0.3M | $14M | $9.2M+ $4.1M short-term inv. | $4.8M-$18M operating cash flow | report ↗ |
| 2022-FY | $0.1M | $12M | $7.2M+ $16M short-term inv. | $4.5M-$17M operating cash flow | report ↗ |
| 2021-FY | $3.1M | $11M | $41M+ $0 short-term inv. | $3.7M-$14M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 1 purchase ($3.0M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-19 | Wasserman Scott M. · director | Award / grant (derivative) | 310,000 | — | — | Form 4 |
| 2026-07-30 | BERMAN DENNIS N · director | Option exercise | 21,854 | $1.26 | $28K | Form 4 |
| 2026-07-30 | BERMAN DENNIS N · director | Option exercise (derivative) | 21,854 | — | — | Form 4 |
| 2026-07-29 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M. · 10% owner; 10% owner; 10% owner; 10% owner | Other (see filing) | 18,030,000 | — | — | Form 4 |
| 2026-07-29 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M. · 10% owner; 10% owner; 10% owner; 10% owner | Other (see filing) (derivative) | 18,030,000 | — | — | Form 4 |
| 2026-06-26 | Munshi Amit · director | Award / grant (derivative) | 155,000 | — | — | Form 4 |
| 2026-06-26 | Aurentz Vincent · director | Award / grant (derivative) | 155,000 | — | — | Form 4 |
| 2026-06-26 | Bellini Roberto · director | Award / grant (derivative) | 155,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 104 reporting institutions held 117.8M shares ($197.5M, 84.0% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Sands Capital Alternatives, LLC | 13,018,965 | $21.9M |
| 2 | Soleus Capital Management, L.P. | 10,875,000 | $18.3M |
| 3 | Fairmount Funds Management LLC | 8,625,000 | $14.5M |
| 4 | Trails Edge Capital Partners, LP | 8,057,345 | $13.5M |
| 5 | ADAR1 Capital Management, LLC | 6,606,572 | $11.1M |
| 6 | Kalehua Capital Management LLC | 6,494,498 | $10.9M |
| 7 | BlackRock, Inc. | 6,303,433 | $10.6M |
| 8 | Blackstone Inc. | 5,938,276 | $10.0M |
| 9 | Siren, L.L.C. | 5,850,000 | $9.8M |
| 10 | Commodore Capital LP | 5,397,488 | $9.1M |
| 11 | VANGUARD CAPITAL MANAGEMENT LLC | 4,450,665 | $7.5M |
| 12 | Saturn V Capital Management LP | 3,863,445 | $6.5M |
| 13 | Spruce Street Capital LP | 3,581,603 | $6.0M |
| 14 | Squadron Capital Management LLC | 3,500,000 | $5.9M |
| 15 | MILLENNIUM MANAGEMENT LLC | 2,928,077 | $4.9M |